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Sequential Intramolecular Epitope Spreading of
Humoral Responses to Human BPAG2 in a Transgenic
Model
Giovanni Di Zenzo1, Valentina Calabresi1, Edit B. Olasz2, Giovanna Zambruno1 and Kim B. Yancey3
Bullous pemphigoid (BP) is a subepidermal autoimmune disease characterized by a humoral response to an
epidermal basement membrane (BM) component, BP antigen 2 (BPAG2). BP patients have IgG autoantibodies
against an immunodominant BPAG2 extracellular domain termed NC16A as well as additional epitopes located
both in the intracellular and extracellular domains (ICD and ECD, respectively) of this autoantigen. To study the
evolution of humoral responses to BPAG2, sequential serum samples obtained from C57BL/6Ncr mice grafted
with otherwise syngeneic skin from transgenic mice expressing human BPAG2 (hBPAG2) in epidermal BM were
studied for IgG reactivity to seven ECD and ICD hBPAG2 epitopes. All grafted mice developed specific IgG
against hBPAG2 ECD and ICD epitopes. In seven of eight mice, anti-hBPAG2 IgG was initially directed against
ECD epitopes; in six mice, humoral responses subsequently targeted additional ECD and ICD BPAG2 epitopes.
In contrast to IgG specific for ECD epitopes, IgG against ICD epitopes was present at lower levels, detectable
for shorter periods, and non-complement fixing. Interestingly, the appearance of IgG directed against ICD
epitopes correlated with the development of graft loss in this experimental model. These studies provide
a comprehensive and prospective characterization of the evolution of humoral immune responses to
hBPAG2 in vivo.
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INTRODUCTION
Bullous pemphigoid (BP) is a subepidermal autoimmune
bullous disease of the skin and mucosae characterized by
a humoral response against structural components of the
cutaneous basement membrane (BM): BP antigen 2 (BPAG2,
BP180 or collagen XVII) and BP antigen 1 (BPAG1, BP230)
(Labib et al., 1986; Stanley et al., 1988). BPAG2 is a type II
transmembrane protein, which consists of a globular cyto-
plasmic domain and a large extracellular region containing
15 collagenous domains (Giudice et al., 1992; Hirako et al.,
1996; Scha¨cke et al., 1998). BPAG1 is a cytoplasmic plakin
protein family member with a central rod flanked by globular
end domains (Stanley et al., 1988; Sawamura et al., 1991).
Although the role of autoantibodies directed against BPAG1
remains to be clarified, the pathogenic relevance of anti-
BPAG2 autoantibodies is supported by several experimental
observations: (1) passive transfer of experimental IgG against
the murine homolog of the immunodominant domain of
human BPAG2 (hBPAG2) elicits subepidermal blisters in
neonatal mice like those seen in patients with BP (Liu et al.,
1993); (2) dermal–epidermal separation is also observed in
neonatal hamsters after passive transfer of rabbit anti-BPAG2
antibodies (Yamamoto et al., 2002); (3) levels of circulating
IgG anti-BPAG2 autoantibodies in patients with BP are
directly related to the disease activity (Haase et al., 1998;
Schmidt et al., 2000; Amo et al., 2001; Hofmann et al., 2002;
Di Zenzo et al., 2008b); and (4) injection of IgG from patients
with BP into BPAG2-humanized mice produces clinical,
histological, and immunopathological alterations like those
seen in affected individuals (Nishie et al., 2007). Most BP
patients have IgG autoantibodies directed against an im-
munodominant extracellular domain (ECD) of BPAG2 termed
NC16A (amino acid (AA) 490–562) (Zillikens et al., 1997).
However, additional epitopes located both in the intra-
cellular domain (ICD) and the ECD of BPAG2 are also
recognized by BP sera (Murakami et al., 1998; Egan et al.,
1999; Nie and Hashimoto 1999; Perriard et al., 1999;
Di Zenzo et al., 2004). The current model of chronic
autoimmune disease involves loss of tolerance to ‘‘dominant’’
self-epitopes that induce inflammatory cascades and tissue
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damage in the target organ. In this model, disease progression
is thought to be associated with recruitment and activation of
autoreactive lymphocytes specific for ‘‘secondary’’ epitopes
on the disease-inducing antigen or on different self-proteins
(Chan et al., 1998). This phenomenon of disease progression
is called epitope spreading (ES). In line with this model, it has
been hypothesized that autoimmune responses in patients
with BP first target BPAG2 ECD epitopes then expand to
include reactivity against ICD epitopes as well.
Recent studies have shown that grafts of skin from
transgenic (Tg) mice expressing hBPAG2 in epidermal BM
elicit experimental humoral immune responses against
hBPAG2 in wild-type (Wt) mice that show fidelity to those
seen in patients with BP (Olasz et al., 2007). To investigate
the dynamics of humoral immune responses against hBPAG2
in this model as well as the potential sequence by which ES
occurs in vivo, serum samples were obtained from Wt mice
at various time points after placement of hBPAG2 Tg skin
grafts and then tested for reactivity against seven BPAG2
epitopes known to be recognized by patients with BP and
other pemphigoid forms (Di Zenzo et al., 2004, 2007, 2008b;
Mariotti et al., 2004; Calabresi et al., 2007). These studies
show that mice grafted with hBPAG2 Tg skin develop
circulating IgG reactive with the majority of BPAG2 epitopes
tested and that reactivity against hBPAG2 ECD epitopes
precedes that against ICD epitopes.
RESULTS
Sera from Wt mice grafted with Tg skin contain IgG that
recognizes numerous ECD and ICD hBPAG2 epitopes
Wild-type C57BL/6Ncr mice grafted with hBPAG2 Tg (but
not syngeneic Wt) skin (Supplementary Figure S1) develop
IgG that binds hBPAG2, including its NC16A immunodomi-
nant domain (Olasz et al., 2007). As adsorption of immune
sera with NC16A did not completely remove its reactivity
against full-length hBPAG2, it was evident that such sera
contained IgG targeting other domains of this antigen (Olasz
et al., 2007). To characterize further humoral immune res-
ponses to hBPAG2 in this experimental model, the reactivity
of IgG from eight Wt mice grafted with hBPAG2 Tg skin 40 or
100 days earlier was analyzed in indirect immunofluores-
cence (IF) microscopy studies of 1 M NaCl split skin and
ELISAs using seven previously characterized ICD and ECD
hBPAG2 epitopes as target antigens (Figure 1). These studies
found that all sera displayed high titers of IgG reactive
with the epidermal side of 1 M NaCl split human skin (titers
ranging from 640 (mouse 8) to 5120 (mice 1, 2, 3, and 5))
(Table 1 and Figure S2). No grafted mouse sera analyzed
(all blood drawn and mice reported in Table 1) develop
IgA or IgE against hBPAG2 (data not shown). In addition,
sera from mice bearing Tg skin grafts were found capable
of fixing C3 to epidermal BM as assessed by indirect IF
microscopy (data not shown). As shown previously (Olasz
et al., 2007), immune sera from Tg graft recipients displayed
no reactivity to the epidermal BM of Wt C57BL6/Ncr mice.
Moreover, sera from Wt mice grafted with gender-matched
syngeneic Wt skin showed no reactivity to human epidermal
BM by indirect IF microscopy or to numerous hBPAG2
recombinant peptides by ELISA. Interestingly, all sera from
hBPAG2 skin graft recipients contained IgG that bound ECD
epitopes encompassing AA residues 490–562 (glutathione-S-
transferase (GST)-NC16A), 1080–1107 (GST-1080), and
1331–1404 (GST-1331). However, only one mouse had IgG
that bound a peptide corresponding to the carboxyl terminus
of BPAG2 (that is, AA 1400–1497 (GST-1400)). Epitopes
encompassing ICD residues AA 151–170 (GST-151) and AA
316–367 (GST-316) were recognized by IgG from five of eight
and seven of eight hBPAG2 skin graft recipients, respectively;
no serum samples in this series contained IgG that reacted
with ICD epitope AA 176–203 (GST-176) (Table 1). The
frequency of reactivity of sera from hBPAG2 graft recipients
showed no obvious correlation with the degree of homology
between murine and hBPAG2 AA sequences (Figure S3).
Anti-hBPAG2 IgG in Wt mice grafted with Tg skin develops first
and foremost against ECD epitopes
Earlier studies have shown that Wt mice grafted with
syngeneic hBPAG2 Tg skin develop high (that is, X640)
and durable (that is, at least as long as 380 days) titers of anti-
hBPAG2 IgG starting 16±2 days after graft placement (Olasz
et al., 2007). The comprehensive ELISA studies described
above show that IgG in grafted mice recognize a variety of
ECD and ICD BPAG2 epitopes, including its NC16A
immunodominant domain. To define in detail the dynamics
of humoral immune responses against hBPAG2, serum
samples were obtained from eight Wt mice at specific time
points after placement of Tg skin grafts and tested for
evidence of IgG reactivity against seven hBPAG2 epitopes
by ELISA. Although no anti-hBPAG2 IgG was detectable in
grafted mice at baseline (that is, the day of grafting), specific
IgG appeared in all eight mice 15–20 days after graft
placement and bound ECD epitopes GST-NC16A, GST-
1080, and GST-1331 (Table 2). ES is defined as occurring
when IgG seroreactivity against a given hBPAG2 epitope is
followed by IgG reactivity against a different epitope. In
seven of eight mice ES events occurred, in particular
serologic reactivity to hBPAG2 was found to extend to ICD
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Figure 1. The seven human BPAG2 (hBPAG2) epitopes studied by ELISA.
Schematic diagram representing hBPAG2 and the position of the seven
fragments produced as glutathione-S-transferase (GST) fusion proteins for use
in this study. Each epitope is termed as GST followed by the number of first
amino acid residue. GST-151, represents a fragment of hBPAG2
encompassing amino acid (AA) residues from 151 to 170; GST-176, AA
176–203; GST-316, AA 316–367; GST-NC16A, AA 490–562; GST-1080, AA
1080–1107; GST-1331, AA 1331–1404; GST-1400, AA 1400–1497. ICD,
intracellular domain; ECD, extracellular domain.
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and/or different ECD epitopes between 20 and 60 days after
graft placement (Table 2). More specifically, in six of eight
mice, anti-hBPAG2 IgG spread toward an ICD epitope (that
is, mice 1, 2, 4, 5, 7, and 8) within 40–100 days of grafting or
a different ECD epitope (that is, mice 1, 4, 5, 6, 7, and 8)
within 20–60 days of grafting (Table 2). Interestingly, ES of
serologic reactivity from one ICD epitope to another was
never detected. These longitudinal epitope mapping studies
also found that the time of appearance of anti-hBPAG2-ICD
IgG closely approximated the date when Tg skin grafts were
deemed lost (range, 13 days before to 4 days after graft loss in
four of six mice (mice 1, 2, 4, and 5)) (Table 2). It was not pos-
sible to assess the correlation between the development of
anti-hBPAG2-ICD IgG and graft loss in two mice (mice 7 and
8) due to the lack of blood samples from relevant time points.
In contrast to anti-hBPAG2-ECD IgG in Tg graft recipients, IgG
against ICD epitopes were present at lower levels, detectable
for shorter periods, and non-complement fixing
The consistency of humoral immune responses in this grafting
model coupled with the ability to use low volumes of serum
in hBPAG2-specific ELISAs facilitated longitudinal studies of
humoral immune responses in Wt mice grafted with Tg skin.
Studies of this sort found that levels of IgG directed against
hBPAG2 ICD epitopes were lower and less durable than
those against ECD epitopes. More specifically, IgG reactivity
against ICD epitope GST-316 decreased and then disap-
peared in three mice (mice 3, 7, and 8) 130–370 days after
grafting, whereas IgG directed against ECD epitopes GST-
NC16A, GST-1080, and GST-1331 remained high (Figure 2
and data not shown). Similarly, the reactivity against the ICD
epitope GST-151 disappeared in three mice (mice 4, 7, and 8)
between days 100 and 570, when reactivities against ECD
epitopes (GST-NC16A, GST-1080, and GST-1331) remained
high (Figure 2 and data not shown). Moreover, in five mice
(mice 1, 3, 5, 7, and 8), relative levels of IgG against ICD
epitopes were lower than those against ECD ones (Figure 2
and data not shown). Finally, ELISA studies of sera from three
representative graft recipients (mice 1, 2, and 5) found that
IgG against hBPAG2 ECD epitopes (GST-NC16A and GST-
1331) was able to fix complement, whereas IgG against ICD
epitopes (GST-151 and GST-316) was not (Figure 3). The
ability of mouse sera to fix complement was also confirmed
by complement-fixing IF assay (data not shown). Interest-
ingly, the analysis of IgG subclasses showed that the
complement-fixing subclasses (IgG2a and 2b) reacted both
with ICD (GST-151) and ECD (GST-NC16A) epitopes in
mouse 5, whereas recognized only ECD epitopes (GST-1331)
in mouse 2 and ECD (GST-NC16A) and only one of two ICD
epitopes (GST-151) in mouse 1 (see inserts of Figure 3). To
extend this study, we then performed a sequential analysis of
IgG subclasses in two grafted mice (mouse 1 and 4) during
the evolution of humoral immune response against four
representative epitopes (GST-151, GST-316, GST-NC16A,
and GST-1331) of hBPAG2. At all the time points positive for
IgG reactivity against hBPAG2, complement-fixing IgG
subclasses bound to ECD epitopes (GST-NC16A and GST-
1331), whereas did not recognize one out of two ICD
epitopes studied (GST-316 in mouse 1 and GST-151 in mouse 4)
(Supplementary Table 1). These data suggest that mouse sera
prevalently contain complement-fixing IgG subclasses react-
ing with ECD epitopes and that hBPAG2 epitopes may
possess different biological capabilities.
DISCUSSION
This study characterizes in detail the specific evolution of
humoral immune responses to hBPAG2 in an in vivo
experimental model in which the immunizing antigen is
located in its natural context (that is, within epidermal BM).
These studies found that (1) Wt mice grafted with hBPAG2 Tg
Table 1. Sera from Wt mice grafted with Tg skin contain IgG that recognizes human epidermal BM and numerous
intra- and extracellular hBPAG2 domains
Mouse serum IIF titer GST-151 GST-176 GST-316 GST-NC16A GST-1080 GST-1331 GST-1400
1 5120 +  + + + + +
2 5120   + + + + 
3 5120   + + + + 
4 1280 +  + + + + 
5 5120 +  + + + + 
6 2560  ND  + + + 
7 2560 + ND + + + + 
8 640 + ND + + + + 
C1 Neg       
Positive sera 5/8 0/5 7/8 8/8 8/8 8/8 1/8
BM, basement membrane; GST, glutathione-S-transferase; hBPAG2, human BPAG2; IIF, indirect immunofluorescence; ND, not done; Neg, negative;
Tg, transgenic; Wt, wild type.
1Representative control serum from a Wt mouse grafted with Wt skin.
Each serum was assayed in duplicate and the mean OD at 450 nm, obtained with GST protein alone (with the correlation wavelength set at 620 nm), was
subtracted from the mean reading obtained with GST epitope. Sera from grafted mice were collected 100 (mice 1, 2, 3, 5, 7, and 8) or 40 (mice 4 and 6) days
after grafting.
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Table 2. Sequential studies of sera fromWt mice grafted with Tg skin show evolution of humoral immune responses
against hBPAG2
Mouse number T1 GST-1512 GST-176 GST-316 GST-NC16A GST-1080 GST-1331 GST-1400
1 (d 733) 0       
20    + + + 
40    + + + 
60 +  + + + + +
100 +  + + + + +
130 +  + + + + +
145 +  + + + + +
2 (d 36) 0       
20    + + + 
40   + + + + 
60   + + + + 
100   + + + + 
130   + + + + 
145   + + + + 
3 (d 50) 0       
20   + + + + 
40   + + + + 
60   + + + + 
100   + + + + 
130    + + + 
145    + + + 
4 (d 50) 0       
20    +  + 
40 +  + + + + 
60 +  + + + + 
100   + + + + 
130   + + + + 
145   + + + + 
5 (d 36) 0       
20      + 
40 +  + + + + 
60 +  + + + + 
100 +  + + + + 
130 +  + + + + 
145 +  + + + + 
6 (d 29) 0  ND     
15  ND   +  
20  ND  + + + 
40  ND  + + + 
7 (d 21) 0  ND     
15  ND   + + 
20  ND  + + + 
100 + ND + + + + 
Table 2 continued on the following page
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skin developed circulating IgG reactive with the epidermal
side of 1 M NaCl split human skin as well as the majority of
hBPAG2 epitopes tested; (2) intramolecular ES of humoral
responses to hBPAG2 occurred in six of eight grafted mice;
(3) during ES, reactivity against hBPAG2 ECD epitopes
preceded those against ICD epitopes; (4) when grafted mice
developed humoral responses against hBPAG2, IgG against
ICD epitopes (in comparison with that against ECD epitopes)
was of lower titer, lesser duration, and non-complement
fixing; and (5) the appearance of IgG directed against
hBPAG2 ICD epitopes correlated with the development of
graft loss. Moreover, five of seven hBPAG2 epitopes were
recognized by sera from the majority of mice grafted with
hBPAG2 Tg skin, showing that the reactivity developed
against hBPAG2 in this model was not restricted to its NC16A
immunodominant domain—findings that again highlight the
similarity between immune responses in this experimental
model and those seen in patients with BP.
The grafting model used in this study allowed the
development of experimental immune responses to BPAG2
in epidermal BM without the influence of adjuvants or
potentially biasing immunization strategies. This approach
allowed the dynamics of humoral immune responses to this
target antigen to be defined prospectively over time and
compared with observations made in patients with BP.
Indeed, the finding that IgG reactivity against hBPAG2 ECD
epitopes in grafted mice preceded (and predominated over)
that against ICD epitopes is in line with recent observations in
BP patients, namely, that humoral immune responses against
BPAG2 initially target ECD epitopes such as NC16A, and
later are directed against ICD epitopes of BPAG2 and BPAG1
(Di Zenzo et al., 2008a). The observed sequence of ES might
have been due to delayed exposure of hBPAG2 ICD epitopes
to the immune system. Delayed exposure of ICD epitopes
may also explain the lower and less durable levels of specific
IgG against this portion of the molecule (in contrast to IgG
against ECD epitopes). Of note, the spread of humoral
immune responses in this graft model was exclusively
Table 2. Continued
Mouse number T1 GST-1512 GST-176 GST-316 GST-NC16A GST-1080 GST-1331 GST-1400
235 + ND + + + + 
370  ND + + + + 
570  ND  + + + 
8 (d 27) 0  ND     
15  ND  +   
20 ND ND  + + + ND
100 + ND + + + + 
235 + ND + + + + 
370 + ND  + + + ND
570  ND  + + + 
d, day; GST, glutathione-S-transferase; hBPAG2, human BPAG2; ND, not done; Tg, transgenic; Wt, wild type.
1Time points after grafting.
2Epitope encompassing amino acid (AA) residues 151–170 (GST-151) produced as GST fusion (see the Result section for the others). Epitope spreading
phenomena are underlined.
3The time of graft loss in recipients is indicated in parenthesis (d, days between graft placement and loss).
Each serum was assayed in duplicate and the mean OD at 450 nm, obtained with GST protein alone (with the correlation wavelength set at 620 nm), was
subtracted from the mean reading obtained with GST epitope.
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Figure 2. Analysis of sera from grafted mice showed that levels of IgG
against ICD epitopes were lower and less durable than those against ECD
epitopes. IgG against specific human BPAG2 (hBPAG2) epitopes at various
time points after grafting was monitored by ELISA. Longitudinal studies of four
representative mice (a, mouse 7; b, mouse 1; c, mouse 3; d, mouse 5) are
shown. Summary data show evolution of serologic reactivity against ECD
(black line) and ICD (dotted line) epitopes. The y axis corresponds to optical
density at 450 nm with the correlation wavelength set at 620 nm.
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target-specific (that is, hBPAG2); in fact, there is no loss of
tolerance against mouse BM epitopes in this model (for
example, mouse BPAG1, mouse BPAG2, and others, data not
shown). In addition, the kinetics of graft loss in this model is
completely different from alloantigen-related graft rejection,
which is extensively shown in a previous paper (Olasz et al.,
2007). The histology of the graft loss in this model is nothing
like GVHD-related graft loss (for example, no interface
dermatitis, no necrotic keratinocytes in the epidermis, and no
satellite cell necrosis). Furthermore, we have shown that the
kinetics of Tg skin graft loss on MHC I/ recipients (that is,
mice with no CD8 cells) are the same as that noted in Wt
recipients, and that graft loss in CD4/ mice was much
delayed and associated with the appearance of anti-BM IgG.
Altogether, these findings have potential implications for
the understanding of antibody-mediated tissue injury in this
and other animal models, as well as in patients with immune-
mediated subepidermal blistering diseases. In addition, the
correlation between the appearance of anti-ICD IgG and graft
loss may signify that antibodies directed against hBPAG2
ECD epitopes (in conjunction with complement) may have
injured basal keratinocytes, and ‘‘exposed’’ hBPAG2 ICD
epitopes. These findings, together with recent observations in
BP patients showing that IgG against BPAG2 ICD epitopes are
detectable early in disease (Di Zenzo et al., 2004, 2008a,
2008b), raise the possibility that the development of IgG
against ICD epitopes may correlate with the initial phase of
the disease when the tissue damage starts occurring.
The demonstration that Wt mice grafted with Tg skin
sequentially and rapidly develop different populations of IgG
reactive with BPAG2 epitopes suggests that the therapeutic
use of decoy peptides to block autoantibody binding in vivo
may be difficult (Nishie et al., 2007). Indeed, such inter-
ventions may require early and aggressive administration
of several different peptide decoys other than those that
correspond to the NC16A immunodominant portion of
BPAG2. Relatedly, it is possible that the administration of
decoy peptides may inadvertently enhance unwanted
immune responses to hBPAG2. The availability of experi-
mental animal models and sensitive screening assays for the
detection of specific IgG will allow future studies to explore
these questions directly.
MATERIALS AND METHODS
Skin grafting studies and sera sampling
Tail skin from hBPAG2 Tg (Olasz et al., 2007) and Wt (control)
C57BL/6Ncr mice was grafted onto the backs of age- and gender-
matched Wt recipients (Rosenberg et al., 1994). Bandages were
removed at day 7 and grafts were inspected daily until day 30, then
weekly, for viability and size. Skin grafts were graded as ‘‘lost’’ if
their area became 20% or less of their original size (McFarland et al.,
2003). Longitudinal studies were conducted on 53 serum samples
obtained at different time points from eight grafted mice (Table 2).
All experimental studies in animals were approved by the Animal
Care and Use Committee at the Medical College of Wisconsin.
IF microscopy
Direct IF microscopy studies of murine skin cryosections were
performed as previously described (Olasz et al., 2007). Serial
dilutions of murine sera were tested against cryosections of intact or
1 M NaCl split human skin by indirect and complement-binding IF
microscopy as described previously (Hodge et al., 1978). Fluor-
escein-conjugated secondary antibodies diluted 1:20 (rat anti-mouse
IgE (g chain specific) and goat anti-mouse IgA (a chain specific)
(SouthernBiotech, Chicago, IL)) were used.
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Figure 3. Analysis of sera from grafted mice showed that IgG against ECD
epitopes was complement fixing in contrast to IgG against ICD epitopes.
Sera from three representative mice (mice 1, 2, and 5) were analyzed at
different time points after grafting for their ability to fix complement on
BPAG2 ECD (GST-1331 (a) and GST-NC16A (b)) and ICD (GST-316 (a) and
GST-151 (b)) epitopes. The sera OD readings from mouse 1 at day 100, 2 at
day 60 and 145, and 5 at day 100 and 130 were higher than cutoff values
calculated for GST-1331 and GST-NC16A ELISAs and lower than cutoff
values calculated for GST-151 and GST-316 ELISAs. In total, 4 representative
normal mice sera out of 10 used as controls are shown. The results are the
mean of data from two or four independent experiments. In the inserts are
shown the IgG subclass distribution of the mice used in complement fixation
studies. d, day; GST, glutathione-S-transferase.
www.jidonline.org 1045
G Di Zenzo et al.
Sequential hBPAG2 Epitope Spreading In Vivo
Production of hBPAG2 peptides
Recombinant peptides corresponding to different portions of hBPAG2
ICDs and ECDs (Figure 1) were produced as previously described
(Mariotti et al., 2004; Calabresi et al., 2007; Di Zenzo et al., 2008b).
ELISAs
Immunomicrotiter plates (Maxisorb Immunoplate, Nunc, Wiesba-
den, Germany) were coated with GST recombinant proteins (400 ng
of GST-NC16A or a molar equivalent of other proteins) and a molar
equivalent of GST in 100ml of coating buffer (50mM NaHCO3, pH
9.6) overnight at 41C. Wells were then washed (phosphate-buffered
saline containing 0.05% Tween 20) and blocked (5% dry no-fat milk
in phosphate-buffered saline containing 0.05% Tween 20). Sera from
grafted mice (diluted 1:100 and supplemented with bacterial
extracts) were added to each well and incubated for 1 h at 371C.
After washing, horseradish peroxidase-conjugated anti-mouse IgG
(Sigma, St Louis, MO), diluted 1:30,000, was added for 1 h at 371C.
Wells were washed and developed with 3,30,50,5 tetramethylbenzi-
dine (Sigma). The reaction was stopped after 20minutes, and OD at
450 nm, with the correlation wavelength set at 620 nm, was
measured using a microplate reader (Bio-Rad Laboratories, Hercules,
CA). For each serum assayed in duplicate, the mean OD reading
obtained with GST was subtracted from the mean reading obtained
with each GST-fusion protein. To measure the complement-fixing
ability of IgG from grafted mice, after serum incubation and washing,
a fresh source of mouse complement (control mouse serum diluted
1:20) was added to each well for 1 h at 371C. After washing,
peroxidase-conjugated anti-mouse C3 (Cappel Lab,
Cochranville, PA), diluted 1:10,000, was added for 1 h at 371C,
washed and developed as above. The cutoff values were determined
as the mean OD readings obtained with 28 and 10 control mouse
sera (Wt and Wt grafted mice) þ 3 standard deviations for ELISA
based on hBPAG2 epitopes and complement-fixing ELISA, respec-
tively. Finally, the subclass distribution of the IgG response to
BPAG2 was assessed by ELISA with grafted mouse sera diluted
1:100. After serum incubation (for 1 h at 371C) and washing, the
antibodies against IgG subclasses (goat anti-mouse IgG1 (g1 chain
specific) diluted 1:5000; goat anti-mouse IgG2a (g2a chain specific)
diluted 1:2000; goat anti-mouse IgG2b (g2b chain specific) diluted
1:2000; goat anti-mouse IgG3 (g3 chain specific) diluted 1:2000, all
HRP conjugated (SouthernBiotech)) were added to each well. The
plates were washed and developed as above. The sensitivity and
specificity of these antibodies at their working dilution was assessed
by using as control substrate-purified mouse monoclonal IgG
subclasses (IgG1, 2a, 2b, 3). The cutoff values were determined as
the mean OD readings obtained with 10 control mouse sera þ 5
standard deviations.
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